Video Interview: Corbus Sees 2016 As Pivotal Year
This article was originally published in Scrip
With key clinical data readouts expected at the end of 2016 and the start of 2017, Corbus Pharmaceuticals Holdings Inc.'s CEO Dr. Yuval Cohen expects the next 12 months to be pivotal for the rare inflammatory disease company. Speaking to Informa Pharma Insights global director of content Mike Ward, Cohen reveals that the company expects to report Phase II data for Resunab, its synthetic endocannabinoid-mimetic compound that binds to the CB2 receptor, in both cystic fibrosis and systemic sclerosis. Phase II data for Resunab in dermatomyositis will be available 1Q 2017.
You may also be interested in...
At ACR: Janssen reported data that show Celltrion’s Remicade biosimilar is not quite the same, but positive sirukumab results may not boost the Janssen and GSK biologic’s market prospects. Meanwhile, Corbus surged on mid-stage resunab results in systemic sclerosis, Janssen shared Phase II gesulkumab psoriasis results, Genentech eyes a new Actemra indication, and Xencor rose on interim Phase II data.
The market for public offerings by biopharma companies is tough, but Corbus Pharmaceuticals, Loxo Oncology and Novavax used three different strategies to raise cash from new and existing shareholders.
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.